Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Altace Sales Declines Reflect King's Inventory Workdown Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Wholesaler inventory reductions of the ACE inhibitor totaled $180 mil. in value in 2004, representing almost all of the 35% decline in Altace sales during the year. Wholesale inventory reductions for Altace and Sonata are continuing as King aims for an on-hand supply of 1.5 months.

You may also be interested in...



Reductions In King Wholesale Inventory Drive Q2 Branded Pharma Sales

King Pharmaceuticals is attributing a rebound in branded pharmaceutical sales during the second quarter in part to lower wholesaler inventories

Reductions In King Wholesale Inventory Drive Q2 Branded Pharma Sales

King Pharmaceuticals is attributing a rebound in branded pharmaceutical sales during the second quarter in part to lower wholesaler inventories

Altace Will Provide "Stable" Growth Platform For Three Years, King Says

King plans to tap the ACE inhibitor's market potential through expanded indications and inclusion of ramipril on hospital discharge protocols, Corporate Head of Commercial Operations Andrzejewski says. The company is targeting the second half of 2005 for NDA filings in pediatric hypertension and chronic kidney disease.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel